Article info
PDFClinical science
Immune checkpoint inhibitors for treatment of periorbital squamous cell carcinoma
- Correspondence to Dr Bita Esmaeli, Orbital Oncology & Ophthalmic Plastic Surgery, Department of Plastic Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA; besmaeli{at}mdanderson.org
Citation
Immune checkpoint inhibitors for treatment of periorbital squamous cell carcinoma
Publication history
- Received July 18, 2021
- Accepted September 27, 2021
- First published October 8, 2021.
Online issue publication
February 20, 2023
Article Versions
- Previous version (8 October 2021).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Author(s) (or their employer(s)) 2023. No commercial re-use. See rights and permissions. Published by BMJ.